P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU

Author:

Chaparro M1,Barreiro-de Acosta M2,Benítez J M3,Cabriada J L4,Casanova M J1,Ceballos D5,Esteve M6,Fernández H7,Ginard D8,Gomollón F9,Lorente R10,Nos P11,Riestra S12,Rivero M13,Robledo P14,Rodríguez C15,Sicilia B16,Torrella E17,Garre A1,Rodríguez-Artalejo F18,García-Esquinas E18,Gisbert J P1

Affiliation:

1. Hospital Universitario de La Princesa- IIS-IP- Universidad Autónoma de Madrid and CIBEREHD, Gastroenterology Unit, Madrid, Spain

2. Complexo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain

3. Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain

4. Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain

5. Hospital Universitario de Gran Canaria Dr. Negrin, Gastroenterology Unit, Las Palmas, Spain

6. Hospital Universitari Mutua Terrasa and CIBERehd, Gastroenterology Unit, Tarrasa, Spain

7. Hospital San Pedro, Gastroenterology Unit, Logroño, Spain

8. Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain

9. Hospital Clínico Universitario ‘Lozano Blesa’- IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain

10. Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain

11. Hospital Universitari i Politecnic La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain

12. Hospital Universitario Central de Asturias and ISPA, Gastroenterology Unit, Oviedo, Spain

13. Hospital Universitario Marqués de Valdecilla, Gastroenterology Unit, Santander, Spain

14. Hospital Universitario San Pedro de Alcántara, Gastroenterology Unit, Cáceres, Spain

15. Complejo Hospitalario De Navarra, Gastroenterology Unit, Pamplona, Spain

16. Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain

17. Hospital General Universitario J.M. Morales Meseguer, Gastroenterology Unit, Murcia, Spain

18. Universidad Autónoma de Madrid/IdiPaz and CIBERESP, Preventive Medicine and Public Health, Madrid, Spain

Abstract

Abstract Background Very few studies have reported updated data on the incidence, clinical evolution and treatment of inflammatory bowel disease (IBD) in Europe. Aims i) To assess the incidence of IBD in Spain; ii) to describe the main epidemiological and clinical characteristics of patients at diagnosis and the evolution of the disease; and iii) to explore the use of drug treatments in the biological era. Methods Prospective and population-based nationwide registry. Adult patients diagnosed with IBD -Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)- during 2017 in all the 17 Spanish administrative regions were included and will be followed-up for 5 years after diagnosis. Treatment was grouped into 5 categories: mesalazine (oral or topical), steroids (intravenous, oral or topical), immunomodulators (thiopurines, methotrexate or cyclosporine), biologics (anti-TNF, vedolizumab or ustekinumab) and surgery. Results 3627 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 millions of adult inhabitants (about 50% of the Spanish population) comprise the study cohort (Table 1). The overall incidence (cases/100.000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U. Incidence of CD was somewhat higher in Central Spain, while that of UC was higher in Northern Spain (Asturias and Navarra) (Figure 1). About 46% of patients had CD and 50% UC. Diagnosis delay was longer in CD than in UC (5 vs. 2 months, p < 0.01). The proportion of patients with symptoms at diagnosis was higher in UC than CD (94 vs. 89%, p < 0.01). By contrast, those with CD vs. UC had higher frequency of family history of the disease (18 vs. 13%, p < 0.01), tobacco smoking (38 vs. 12%, p < 0.01) and extraintestinal manifestations (12 vs. 6%, p < 0.01). At diagnosis, 18% of CD patients had structuring or fistulising behaviour, and 69% of UC patients had extensive colitis or left-sided colitis. During a median of 12-month of follow-up, 28% of patients were hospitalised (35% of CD and 22% of UC patients, p < 0.01). A total of 2.6% CD patients progressed to a more severe phenotype, and 2% UC patients developed a more extensive involvement. The cumulative exposure to different treatments is shown in Figure 2. Conclusion The incidence of IBD in Spain is quite high and similar to that reported in Northern Europe. IBD patients require the use of substantial therapeutic resources, which are greater in CD than in UC, and much greater than previously reported. One third of patients are hospitalised in the first year after diagnosis and over 5% undergo surgery. These results highlight the high burden of IBD as well as some of the important challenges faced by clinicians and healthcare systems to manage this costly and complex disease.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3